PosterSessionOnline

INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTA..

ISTH 2024 Congress

June, 22-26 Bangkok

N. Poster

Poster title

Applicant name

Status


PB-0013	Protein carbonylation in patients with COPD and effects of statin treatment: a randomized controlled trial	Anna Hojda	Received

PB-21	Training future leaders in antithrombotic management: the Certificate of Advanced Studies in Antithrombotic Management (CAS-AM)	Hugo ten Cate	Received

PB-0027	Time to Bleeding After DOAC initiation for Venous Thromboembolism or Atrial Fibrillation	Jordan Schaefer	Received

PB-0028	Multi-center Adoption and Impact of a DOAC Dashboard to Reduce Off-Label DOAC Prescribing	Geoffrey Barnes	Received

PB-0030	Relationship between stroke history and the occurrence of adverse events after mitral valve replacement in patients with atrial fibrillation combined with heart valve disease	xinsheng Yan	Received

PB-0036	Increased complement activation markers in antiphospholipid syndrome-related ischemic stroke correlate with platelet hyperreactivity	Ibrahim Tohidi-Esfahani	Received

PB-0046	Percent Reduction From Baseline Is a Better Target Than Follow-Up Levels in Low-Density Lipoprotein Cholesterol Lowering Therapy For Patients With Acute Myocardial Infarction	Kyung Hoon Cho	Received

PB-0049	Fibroblast Growth Factor 23 is Associated With High-sensitivity Cardiac Troponin I, T and Left Ventricular Hypertrophy in Patients With Chronic Kidney Disease	satoshi fujii	Received

PB-0050	FGF23 Mediates Cardio-Renal Interaction in Asymptomatic Subjects With Chronic Elevation of Serum High-sensitivity Troponin: Implications for Multisystem Cardio-renal Risk	Satoshi Fujii	Received

PB-0051	Rapid eGFRcys Decline Closely Correlates With Episodes of Acute Coronary Syndrome in Asian Patients with Type 2 Diabetes	Satoshi Fujii	Received

PB-0058	Socio-demographic and lifestyle factors associated with cardiovascular disease in a large prospective cohort of healthy subjects	Anna Falanga	Received

PB-0062	Rural-Urban Based Differences in Patients with Thromboangiitis Obliterans (Buergers Disease): Insights from Nationwide Inpatient Sample	Wenzhu Li	Received

PB-0064	Relationship of decreased levels of omentin-1 with insulin resistance and prothrombotic state in peripheral vascular disease	Oleksii Korzh	Received

PB-0069	The assessment of the role of ROTEM in thrombosis risk evaluation of the severe form of COVID 19 patients	Viola Popov	Received

PB-0070	Fluorescence cross-correlation spectroscopy based measurement of von Willebrand factor multimer size for classifying patients with acquired von Willebrand syndrome	Lausonia Ramaswamy	Received

PB-0073	FIX Post infusion monitoring surveys: Results and analysis from the updated UK NEQAS BC Haemophilia programmes 2024	CHRISTOPHER REILLY-STITT	Received

PB-0074	Experience of interpretating F8 missense variants using F8-specific variant interpretation guidelines published by the ClinGen Coagulation Factor Deficiency Expert Panel	Yohann JOURDY	Received

PB-0077	Urinary thromboxane to assess thromboinflammation: a future biomarker for precision medicine	JEFFREY DAHLEN	Received

PB-0079	Experience of Lupus anticoagulant laboratory diagnosis by applying the 2020 ISTH-SSC guidelines from a single tertiary care center in Kerala	Reema Abraham	Received

PB-0081	Evaluation of a new Stago system sthemO dRVV screen and confirm on sthemO 301 coagulation analyzer for lupus anticoagulant detection	Sylvain LAMOINE	Received

PB-0083	Investigating genotype-phenotype relationships in thrombosis patients with PROC, PROS1 or SERPINC1 variants	Christine Van Laer	Received

PB-0084	Super formula for soluble C-type lectin-like receptor 2 x D-dimer in patients with acute cerebral infarction	Hideo Wada	Received

PB-0085	The evaluation of hemostatic abnormalities in congenital or acquired coagulation factor deficiency using a clot waveform.	Hideo Wada	Received

PB-0086	Factor V and VII assay discrepancies in the UK NEQAS Blood Coagulation (BC) programme comparison with International Society on Thrombosis and Haemostasis (ISTH) SSC plasma standard results	Ian Jennings	Received

PB-0087	Evaluation of the new Stago system, sthemO II, sthemO V and sthemO X on sthemO 301 analyzer for factors II, V and X deficiencies determination	Sylvain LAMOINE	Received

PB-0089	Unfractionated Heparin measurement with Anti-Xa assays from the UK National External Quality assessment Blood Coagulation 2023.	CHRISTOPHER REILLY-STITT	Received

PB-0091	Fast screening of direct oral factor Xa inhibitors, interferences in anti-Xa assays	An Stroobants	Received

PB-0092	D-dimer kinetic variations on sthemO 301 to predict bleeding complications in ECMO patients	Matthieu Bourdin	Received

PB-0094	A Novel, Point-of-care (POC) Portable Meter & Disposable Card, Viscoelastic Coagulation Diagnostic Platform for Hemostasis Management with complete results including fibrinolysis in under 10 minutes	Abhishek Ramkumar	Received

PB-0098	Homogeneous Enzyme Immunoassay for the Direct Determination of Apixaban in Human Plasma	Raj Singh	Received

PB-0099	Homogeneous Enzyme Immunoassay for the Direct Determination of Rivaroxaban in Human Plasma	Raj Singh	Received

PB-0101	Evaluation of the new Stago system sthemO Anti-Xa M on sthemO 301 analyzer for monitoring heparin therapy.	Joffrey Feriel	Received

PB-0103	A retrospective study of causes of prolonged PT in outpatient setting from a single tertiary care centre in southern India	Reema Abraham	Received

PB-0104	International Normalised Ratio measurement data from the UK National External Quality Assessment for Blood Coagulation programme 2023.	CHRISTOPHER REILLY-STITT	Received

PB-0106	Stability of cardiac biomarkers during long-term biospecimen banking	JEFFREY DAHLEN	Received

PB-0108	External quality control for hemophilia laboratories: five year experience of the Italian Hemophilia Centers	Angelo Claudio Molinari	Received

PB-0115	Pre analytical variables: A take on haemolysis and ways of dealing with it as reported by the United Kingdom National External Quality Assessment Scheme for Blood Coagulation (UK NEQAS BC).	IAN JENNINGS	Received

PB-0116	Pre analytical variables: Haemolysis Supplementary Exercise, a report from United Kingdom National External Quality Assessment Scheme for Blood Coagulation (UK NEQAS BC)	IAN JENNINGS	Received

PB-0117	Nordic Biomarker MRX PT DOAC assay on Sysmex CN6000 Analysers	Jackie Dobson-Storr	Received

PB-0119	Lab Modified Test in Detection of Antithrombin Deficiency in era of IVDR/FDA Requirements	Kieron HICKEY	Received

PB-122	Automated algorithm for interpretation of functional Lupus anticoagulant testing	Chiara Adele Elena Novelli	Received

PB-0124	Establishment of reference intervals for platelet aggregation tests on new automated coagulation analyzer	Desiree Coen Herak	Received

PB-0125	Clinical performance evaluation of a new Stago system for Factor IX level determination: sthemO IX on sthemO 301	Joffrey Feriel	Received

PB-0126	Clinical performance evaluation of a new Stago system for Factor VII levels determination: sthemO VII on sthemO 301 with sthemO PT	Joffrey Feriel	Received

PB-0129	Overcoming High Optical Densities in a Chromogenic assay	Sunny Jamati	Received

PB-0132	Determination and verification of reference intervals on the new Stago coagulation analyzer sthemO 301	Joke Konings	Received

PB-0139	Clinical performance evaluation of a new Stago system for Factor VIII level determination: sthemO VIII on sthemO 301	Joffrey Feriel	Received

PB-0149	Detection of thrombotic state using a clot waveform analysis	Hideo Wada	Received

PB-0157	Viscoelastic tests as screening in congenital hemorrhagic disease, cases report. Instituto Nacional de Pediatria, Mexico City, Mexico	MARA NUNEZ TOSCANO	Received

PB-0159	Assessment of the impact of underfilled samples on Coagulation laboratory tests using Sysmex CN6000 analysers.	Lee Beckett	Received

PB-0164	Identifying the differences in the structural etiology underlying coagulation Factor XIII mutations based on a 2.4 cryo-EM structure of the coagulation Factor XIII-A2B2 complex.	Sneha Singh	Received

PB-0169	Direct relation between hypercoagulability and high fibrinogen levels measured by thrombelastography in patients with high-risk coronary artery disease and COVID-19	Jeffrey Dahlen	Received

PB-0170	Preoperative biomarker panel with fibrinogen and FVIII improves prognostic evaluation of pancreas cancer with neoadjuvant therapy	Riitta Lassila	Received

PB-0177	D-dimer Inversely Correlates with Neurocognitive Performance in Atrial Fibrillation: A 7-year Follow Up study	Pratintip Lee	Received

PB-0200	Clinical outcomes from treatment with extended half-life and standard half-life products in a hemophilia patients cohort in Colombia	SASKIA PRASCA	Received

PB-0209	Effectiveness and safety of efmoroctocog alfa (a recombinant factor VIII Fc) across body mass index (BMI) categories: pooled data from two non-interventional phase 4 studies (A-SURE/PREVENT)	Daniela Bruni	Received

PB-0212	Evaluation of Omfiloctocog alfa (SCT800) Efficacy in Real-World Treatment of Severe Hemophilia A in China: Insights from the SURPASS Study	Sen Yu	Received

PB-0214	Synovial immune and inflammatory gene regulation is influenced differently by recombinant FVIII or FVIII-Fc fusion protein after hemarthrosis in FVIII-deficient mice	Bilgimol Chumappumkal Joseph	Received

PB-219	The World Federation of Hemophilia Living Guidelines Model	Donna Coffin	Received

PB-0221	Persistent and stable therapeutic levels of transgenic FVIII expression following AAV delivery to adult and infant hemophilic dogs	Laura Swystun	Received

PB-223	Standardized and Centralized Global Database on Gene Therapy Data The World Federation of Hemophilia Gene Therapy Registry	Donna Coffin	Received

PB-0224	Inflammatory cytokine expression after hemarthrosis differs with recombinant FVIII and FVIII-Fc fusion replacement in Factor VIII-deficient mice	Bilgimol Chumappumkal Joseph	Received

PB-0225	High Bleed Control with a Single 225 g/kg Eptacog Beta Dose in Adult and Adolescent Hemophilia A or B Persons with Inhibitors	Thomas Wilkinson	Received

PB-0229	Results from the Taiwanese cohort in GENEr8-1: bleeding rates, factor VIII usage, quality of life and safety in severe Hemophilia A patients after gene therapy	Teresa Raquel Moraes Ramos	Received

PB-0232	Measuring FVIII inhibitors in samples containing emicizumab: results of a multi-laboratory field study	Geoffrey Kershaw	Received

PB-0235	Trial-in-progress: A two-part open-label study of an in vivo CRISPR/Cas9-based coagulation factor IX targeted gene insertion therapy (REGV131-LNP1265), in participants with hemophilia B (BEYOND-9)	Meagan OBrien	Received

PB-0236	Evaluation of real-world peri-operative outcomes in patients with haemophilia A (HA) with or without inhibitors on emicizumab prophylaxis in Australia	Radha Ramanan	Received

PB-0238	Clinical and patient-centered outcomes among Italian people with severe haemophilia A receiving prophylaxis: real-world findings from Cost of Haemophilia: a Socio-economic Survey (CHESS) data base	rita carlotta Santoro	Received

PB-0242	A phase I trial evaluating safety and pharmacokinetics in human and an ex vivo pharmacodynamics study in hemophilia patients of KN057, the first antiTFPI monoclonal antibody in China	Feng Xue	Received

PB-0243	Detection of an anti-drug antibody against emicizumab in clinical practice: experience from one center in France	Claire Auditeau	Received

PB-0249	Development of the first small molecule therapy for the treatment of hemophilia A and B	Ashay Gore	Received

PB-0251	Indirect comparison of prophylaxis efficacy between simoctocog alfa and efanesoctocog alfa in severe hemophilia A and their cost in the United States	Greg Melroe	Received

PB-0254	The Experience of Using Damoctocog Alfa Pegol During Surgery in Patients Treated at the Bonn Center	Darwin Health Communications Darwin Health Communications	Received

PB-0255	Comparison of FVIII and concizumab in thrombin generation assays under different conditions	Jacob Lund	Received

PB-260	Evaluating Effectiveness and Safety in the Fourth Interim Analysis of the HEM-POWR Study: A Post Hoc Analysis of Patients From Nordic Study Sites	Jennifer Humbert	Received

PB-261	Investigating effectiveness and safety of extended dosing regimens of damoctocog alfa pegol in the real-world HEM-POWR study	Doreen Kruk	Received

PB-0262	Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and without FVIII inhibitors: Third interim analysis of the non-interventional study EMIIL	Katrin Blumbach	Received

PB-0267	Long-read nanopore sequencing used for comprehensive structural variant characterization in severe hemophilia patients.	Nina Borràs Agustí	Received

PB-0271	Health Literacy of People with Haemophilia in China Results of a Cross-sectional, Community-Based Survey	Karina Hsu	Received

PB-0279	Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders	Shannon van Hoorn	Received

PB-0290	Status of von Willebrand disease in a cohort of Colombian patients 2022-2023	Gina Alejandra Diaz Mosquera	Received

PB-0298	Functional multiplex activity assay reveals molecular perturbations in ADAMTS13 structure and composition	Frida Miranda	Received

PB-0299	The dual neuroprotective and anti-inflammatory effects of acute constitutively active ADAMTS13 administration in preclinical models of intracerebral haemorrhage	Chiara Ramponi	Received

PB-0302	ADAMTS13 can be a novel therapeutic option for acetaminophen-induced acute liver injury in mice	Akihiro Sawa	Received

PB-0303	The role of VWF-ADAMTS13 axis in the pathogenesis of lung inflammation in mice	Kohei Tatsumi	Received

PB-0307	ADAMTS13 activity method Comparison	Thomas Pitchford	Received

PB-0309	ADAMTS13 activity as a novel biomarker in sepsis	Joshua Muia	Received

PB-0313	A cohort study of 22 patients with immune-mediated thrombotic thrombocytopenic purpura in Taiwan	Hsuan-Yu Lin	Received

PB-0317	Unravelling the disulfide-bonded states of antithrombin: Implications for anticoagulant activity	Kenny Ningxin Lu	Received

PB-0319	Reduced plasma selenoprotein P is associated with type I antithrombin deficiency and prothrombotic clot phenotype	Anna Hojda	Received

PB-0326	The synergistic effects of hypoxia and estrogen on Protein S gene expression	Mohammad A Mohammad	Received

PB-0343	Localized recombinant human von Willebrand Factor influences in vivo angiogenesis in VWF-deficient mice	Edwin Ocran	Received

PB-0345	The novel variable heavy chain antibody Syn-VWFA1 inhibits platelet von Willebrand factor interaction in solution	Joke Konings	Received

PB-0348	High shear rate thrombi occlude blood flow by a cable of VWF and platelets	Edouard Machenaud	Received

PB-0350	Deficiency of ultra-large von Willebrand factor multimers at diagnosis is associated with poor prognosis in acute immune-mediated thrombotic thrombocytopenic purpura.	Noritaka Yada	Received

PB-0356	Acquired von Willebrand syndrome secondary to monoclonal gammopathy: a single centre case series.	Quentin Van Thillo	Received

PB-0361	Acquired von willebrand disease in the diagnosis of IgM multiple myeloma	Cecilia Guillermo	Received

PB-0371	The utility of D-dimer in excluding the diagnosis of proximal deep vein thrombosis in the anticoagulated population	Bobby Gouin	Received

PB-0372	Significance of omentin-1 and visfatin in platelet activation and blood coagulation in patients with venous thromboembolism	Oleksii Korzh	Received

PB-0378	Incidence of venous thromboembolic disease in covid-19 patients during hospitalization and within 90 days after discharge	Carina Pizzarossa	Received

PB-0381	Anticoagulant treatment for isolated distal deep vein thrombosis: A systematic review and meta-analysis	Walter Ageno	Received

PB-0384	Antibodies against factor XI/factor XIa effectively anticoagulate without increasing bleeding risk in cynomolgus monkeys	Dan Chalothorn	Received

PB-0389	Estimating in hospital and post-discharge venous and arterial thrombotic events in patients with COVID-19	Rushad Patell	Received

PB-0392	Cost-effectiveness of Venous Thromboembolism Prophylaxis Protocol Implementation Compared to Routine Clinical Practice in a Tertiary Hospital in Thailand	Nutsiri Kittitirapong	Received

PB-0396	Understanding venous thromboembolic research end-user perspectives: A qualitative exploration to shape a core outcome set for venous thromboembolism treatment studies (VTE-COS)	Lisa Duffet	Received

PB-0397	Long-term anticoagulation management in patients with venous thromboembolism: evaluation of an outpatient clinic led by a nurse practitioner	Tessa Elling	Received

PB-0404	Risk of venous thromboembolism is not increased with short-term PM2.5 air pollution even among at risk groups	Scott Woller	Received

PB-407	Designation and application of Multi-dimensional continuous management index system for high-risk VTE discharged patients	Ying Yang	Received

PB-0410	Clinical Outcomes of Enoxaparin 30 mg for Venous Thromboembolic Prophylaxis in Low-Weight Surgical Patients: A Retrospective Cohort Study	Amjaad Alfahed	Received

PB-415	Peri-operative VTE prophylaxis: call on an action	Ying Yang	Received

PB-0419	Artificial Intelligence and Venous Thromboembolism: Talking to the Experts	Rushad Patell	Received

PB-425	Smart technology facilitated patient-centered venous thromboembolism management:A focus group study of patient priorities	Yutao Guo	Received

PB-0432	Smart technology facilitating patient-centered venous thromboembolism management : pilot assessment for the adherence	Zheqi Zhang	Received

PB-440	Progestin drugs are not associated with an increased risk of thrombotic events in patients with severe inherited thrombophilia. A single-center retrospective cohort study	Nicola Perin	Received

PB-0454	Women who achieved pregnancy after ovarian stimulation show prothrombotic fibrin clot phenotype compared to non-pregnant women: associations with neurohormones	Anna Hojda	Received

PB-0464	D-dimer ratio to re-establish trimester-specific reference ranges of D-Dimer in pregnant women: a pooled study.	jia Du	Received

PB-0474	Should anticoagulation be administered in all pregnant women with hereditary antithrombin deficiency?	Maria Teresa De Sancho	Received

PB-0475	Thrombotic Microangiopathy during Pregnancy: The Role of ADAMTS13 Activity	Eleni Gavriilaki	Received

PB-0485	Risk of venous thromboembolism in pregnant women hospitalized with severe infections: prospective analysis of 352 charts.	Venina Barros	Received

PB-492	Fourth interim analysis of the HEM-POWR Study: A post hoc analysis of real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Taiwan	Doreen Kruk	Received

PB-0493	SINGLE CENTER CROSS-SECTIONAL STUDY ON HEALTH RELATED QUALITY OF LIFE IN PEOPLE WITH HEMOPHILIA	Angelo Claudio Molinari	Received

PB-0495	Treatment of Thrombotic Cardiovascular Diseases in People with Haemophilia: A Japanese Consensus Study	Azusa Nagao	Received

PB-0497	smart medication Gene a collaboration and documentation platform according to hub & spoke model for gene therapy of hemophilia A/B	David Schmoldt	Received

PB-0503	Clinical outcomes of people with hemophilia B treated with N9-GP in real-world settings: the Adelphi Disease Specific Programme hemophilia study	Shwetha Shivamurthy Prashanth	Received

PB-0505	Long-term joint health outcomes with a recombinant factor VIII Fc from the 48-month prospective, observational A-MORE study: Third interim analysis of up to 24 months	Daniela Bruni	Received

PB-0514	Joint health in patients with hemophilia: data from real-life practice in Colombia	Saskia Pasca Tapia	Received

PB-519	Does emicizumab prophylaxis lead to FVIII inhibitor reduction in hemophilia A patients with positive inhibitors?	Marija Milos	Received

PB-0521	The change in Haemophilia A therapy in Germany - a retrospective data analysis of product classes from smart medication ScanDoc documentation platform used in pharmacies	David Schmoldt	Received

PB-523	Interim results from a non-interventional, post authorisation safety study of nonacog beta pegol as routine prophylaxis in patients with haemophilia B	Robert Klamroth	Received

PB-524	Burden of difficult venous access in patients with Hemophilia A - Results from DIVA real-world data research	Emina Suljovic Hadzimesic	Received

PB-0535	How much is the coagulation ability of emicizumab in hemophilia A patients treated with it, when converted to factor VIII activity?	Teruhisa Fujii	Received

PB-0539	Analysis of emicizumab plasma concentrations in single centre cohort of people with Haemophilia A on emicizumab prophylaxis	Lucy Neave	Received

PB-0543	Experience of switching to EHL-CFVIII or non-replacement therapies in patients with severe or moderate hemophilia a without inhibitor from the galician community: retrospective analysis	Michael Calviño Suárez	Received

PB-0547	A Canadian Roundtable Discussion of the Peri-operative Use of Nonacog beta pegol (N9-GP) for Persons with Moderate to Severe Hemophilia B	Man-Chiu Poon	Received

PB-0553	Epidemiological survey and data analysis of hemophilia patients in Henan Province of China	Bingjie Ding	Received

PB-0558	Efficacy, Safety and Quality of Life Three Years After Gene Transfer With Valoctocogene Roxaparvovec in a Brazilian Cohort	Teresa Raquel Moraes Ramos	Received

PB-0565	Phenotypic characterisation of congenital fibrinogen disorders in Australia	Radha Ramanan	Received

PB-0569	Autosomal Recessive Factor XI Deficiency Caused by a Common Ashkenazi Jewish Variant and a Novel, de novo Missense Variant	miguel escobar	Received

PB-579	Safety of continuous long term antifibrinolytic therapy in patients with Hereditary Hemorrhagic Telangiectasia	Sheh-Li Chen	Received

PB-0591	Differences in Types of Thromboses and Risk Factors in Males versus Females in Adolescent Thromboembolism in the Throm-PED Registry	Lakshmi Srivaths	Received

PB-598	Primary role in assessing the risk of severe early onset preeclampsia of phospholipid-dependent procoagulant clotting time and initiation phase of thrombin generation test	patrick Van Dreden	Received

PB-0600	Tissue factor, leukemia inhibitory factor , thrombomodulin, D-Dimer, thrombin generation and procoagulant phospholipid dependent clotting time are predictive for in vitro fertilization outcome	patrick Van Dreden	Received

PB-0605	Real World Data on Safety and Efficacy of Emicizumab in Previously Untreated and Minimally Treated Patients under 18 months	Eman Hassan	Received

PB-0606	Bone Health Screening for Pediatric Patients on Chronic Warfarin Therapy: A Quality Improvement Initiative	Vilmarie Rodriguez	Received

PB-0615	Racial and age-specific differences in Rotational Thromboelastometry (ROTEM) and conventional coagulation laboratory tests in a healthy pediatric population	Marium Malik	Received

PB-0641	The benefits of prophylaxis with low dose factor VIII in the treatment of severe haemophilia A in Limpopo, South Africa.	Jean Paul Tshipeng	Received

PB-0654	Hospital-acquired venous thromboembolism among critically ill children undergoing invasive ventilation for acute respiratory failure is associated with impaired clot formation and fibrinolysis	Steven Bruzek	Received

PB-0659	Filtration of heparin during preparation of a cardiopulmonary bypass circuit priming solution for infants.	Paul Davies	Received

PB-0661	Platelet response following dexamethasone in obese vs. non-obese patients with primary, acute immune-mediated thrombocytopenia	Jeffrey Gilreath	Received

PB-0662	CyTOF and microRNAs reveal possible biomarkers for early diagnosis and treatment of Heparin Induced Thrombocytopenia (HIT).	Theodora Kostelidou	Received

PB-0666	Comparison Of Interobserver Agreement Between The 4T And The HIT Expert Probability (HEP) Scores	Albaraa Madkhali	Received

PB-0669	Impact of the use of intravenous immunoglobulins and prednisone on newborns of mothers with platelet alloimmunization- a retrospective observational study	Stephanie Lord	Received

PB-0694	Heavy menstrual bleeding is a common, underrecognized issue in at risk adolescents with immune thrombocytopenia and inherited platelet disorders.	Michele Lambert	Received

PB-0700	Identifying Unmet Needs Related to Treatment and Disease Control in Immune Thrombocytopenia (ITP): US Patient Survey	Shannon Campbell	Received

PB-0708	Heparin-induced thrombocytopenia among patients with end-stage renal disease in Gombe, Nigeria	Saleh Yuguda	Received

PB-0719	Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: a case report	Naidan Zhang	Received

PB-0728	Role of the mechanotransductor PIEZO1 in megakaryocyte differentiation	Christilla Bachelot-Loza	Received

PB-0741	Platelet Count Recovery as a Pragmatic Diagnostic Tool for Predicting Mortality after Cardiac Surgery	Nathan Clendenen	Received

PB-0748	Identification of key regulators of procoagulant COAT platelet generation by quantitative temporal phosphoproteomic analysis	Alessandro Aliotta	Received

PB-0759	MicroRNA-223-3p decreases platelet procoagulant activity through the regulation of TMEM16F	Pierre Fontana	Received

PB-0771	Testosterone Replacement Therapy Does Not Alter Stored Platelet Hemostatic Capacity	Kimberly Thomas	Received

PB-0781	Liposome-assisted uptake of procoagulant proteins by platelets	Herm Jan Brinkman	Received

PB-0787	Role of ed microRNAs in regulation of hemostasis in zebrafish larvae	Pierre Fontana	Received

PB-0808	The L33P polymorphism of integrin 3 PSI domain displays enhanced thiol isomerase activity and upregulates the coagulation cascade	Heyu Ni	Received

PB-0830	Mechanisms of 4-Hydroxy-2-nonenal (HNE)-induced thromboinflammation	Shabbir Ansari	Received

PB-0832	Targeting endothelial dysfunction when treating convalescent COVID-19 patients from a moderate or severe clinical presentation and the effect on serum biomarkers. A randomized placebo-controlled trial	Alejandro gonzalez ochoa	Received

PB-0856	Antiplatelet Effects of Hydroxychloroquine in Patients with Systemic Lupus Erythematosus evaluated by Total Thrombus-formation Analysis System (T-TAS)	Daisuke Hiraoka	Received

PB-0862	Targeting Neutrophil Extracellular Trap Formation under Flow in Patients with Immune Thrombotic Thrombocytopenic Purpura	Noritaka Yada	Received

PB-0878	Physiologically Relevant NETosis Induction Reveals Distinct Triggers and Chromatin Changes	Maisie Spurling	Received

PB-0880	Risk stratification utilizing Sequential Organ Failure Assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC)	Tomoki Tanigawa	Received

PB-0883	Platelet Function Testing in Sepsis	Dermot Cox	Received

PB-0892	Risk of venous thromboembolism with short-term ozone air pollution among at-risk groups &8203;	Scott Woller	Received

PB-0914	Prevalence of Thromboembolic disease associated with hospitalization in Hospital de Clinicas-Uruguay from January 2021 to December 2022	Maria Cecilia Guillermo Esposito	Received

PB-0923	Biomarkers for prediction of thrombus resolution after acute deep vein thrombosis in the lower extremities	Damon Houghton	Received

PB-0930	Hypoxia and right ventricular strain in patients with acute pulmonary embolism	Christopher Kabrhel MD MPH	Received

PB-0932	Safety and efficacy of low molecular weight heparin in patients with acute venous thromboembolism post-thrombolytic therapy as compared to unfractionated heparin: A systematic Review and Meta-analysis	Eman Mansory	Received

PB-0938	Clinical Factors Associated with Low Antithrombin Activity Among Patients with Acute Pulmonary Embolism: The Thromboembolism Heparinization and AntithrombiN Observational Study (THANOS)	Christiana Prucnal MD ScM	Received

PB-0945	Isolated deep vein thrombosis and isolated pulmonary embolism - are there any differences?	Jana Hirmerova	Received

PB-946	The wide spectrum of pulmonary thromboembolism on electron microscopy and clinical implications	Arthur Freedman, M.D.	Received

PB-0949	Whole PROC gene sequencing to explain genetically unresolved protein C deficiency.	Yohann Jourdy	Received

PB-0950	An APS ACTION international Core laboratory performance assessment of Lupus Anticoagulant test by Taipan and Ecarin snake venom clotting times	Hannah Cohen	Received

PB-0954	Co-occurrence of extremely rare ENG S484S and V504M variants in two independent women with unexplained venous thrombosis.	David-Alexandre Trégouët	Received

PB-0964	Endothelial activation of protein C is disproportionately impaired in hereditary protein C deficiency	Nadine Schwarz	Received

PB-0968	Evaluation of an automated Protein C antigen assay	Thomas Pitchford	Received

PB-0970	Klippel-Trenaunay Syndrome: a rare disorder with complex hemostatic and thrombotic challenges	Markie Zimmer	Received

PB-0972	Germline JAK2 V617F Variant in Patient with Unprovoked Cerebral Venous Sinus Thrombosis	miguel escobar	Received

PB-0974	Exploring Acquired Thrombophilia: Insights from a 5-Year retrospective analysis of patients with venous thrombosis in a tertiary care centre in south India.	Gohul Jalajakumari	Received

PB-0977	Bovine thrombin-associated antiphospholipid syndrome	Markie Zimmer	Received

PB-0984	The Incidence of Major Bleeding and Case Fatality Rates in Patients Anticoagulated with Factor Xa Inhibitors: An Observational Study in the UK Clinical Setting (AXIOM UK)	JB Mamza	Received

PB-0985	Evaluating a universal calibrator for anti-Xa testing in patients taking rivaroxaban and apixaban	Emma Leitinger	Received

PB-0988	Assessing andexanet alfa Prescribing and Administration Practices: A Single Institution Study to Improve Patient Safety	Marwan Shaikh	Received

PB-0990	Efficacy of a Platelet-derived Hemostatic Agent in Reversing P2Y12 Antagonist Therapy in Vivo	Thomas Diacovo	Received

PB-0992	Impact of thrombocytopenia on bleeding and thrombotic complications in patients with atrial fibrillation starting anticoagulation: a time varying analysis.	Kevin Barnum	Received

PB-0993	Anticoagulation stewardship: The new standard of care in anticoagulant safety. Experiences from a large, tertiary, multicentre health service.	Emma Leitinger	Received

PB-1000	Estimates of 2024 Preventable Deaths in US Patients Treated with Apixaban and Rivaroxaban Requiring Reversal for Major Bleeding Events	Charles Mahan	Received

PB-1001	Anticoagulation for Venous Thromboembolism (VTE) in patients aged 80 years: a focus on bleeding	Jignesh Patel	Received

PB-1004	D-dimer monitoring to guide anticoagulation management in patients receiving venoarterial-extracorporeal membrane oxygenation: a retrospective cohort study	Litao Zhang	Received

PB-1009	Assessment and Management of Toxic Coagulopathies at the Yeolyan Hematology and Oncology center: A 7-Year Retrospective Analysis (2016-2022)	Heghine Khachatryan	Received

PB-1015	Application of Thromboelastography in Pediatric Liver Transplantation: Insights from Mexican Patients. Instituto Nacional de Pediatria, Mexico City, Mexico	MARA NUNEZ TOSCANO	Received

PB-1016	Incidence and risk factors for early bleeding complications in patients with acute myeloid leukemia	Radhika Gangaraju	Received

PB-1019	Diagnostic criteria for heatstroke-induced coagulopathy: a retrospective study from 24 hospitals	Qingwei Lin	Received

PB-1020	Acquired Haemophilia Spanish registry, characteristics of infectious complications after 10 years activity	Maria Eva Mingot-Castellano	Received

PB-1022	Protenmic reveals nafamostat mesylate Improves Survival Rate of Rats with Exertional HeatStroke	Qingwei Lin	Received

PB-1023	Development of Sepsis induced Coagulopathy is associated with death in late onset sepsis in Neonates	Daniel OReilly	Received

PB-1024	Disseminated intravascular coagulation predicts a poor prognosis for out-of-hospital cardiac arrest patients receiving veno-arterial extracorporeal membrane oxygenation	Satoshi Gando	Received

PB-1038	Hemostasis disorders induced by Bothrops atrox and Bothrops lanceolatus venoms: in vivo study	Georges Jourdi	Received

PB-1046	Elevated International Normalized Ratio Contributes to Poor Prognosis in Patients with Traumatic Lung Injury	Qingwei Lin	Received

PB-1049	ROTEM Thromboelastometry System- Caution in interpretation	Vishnu Prasad	Received

PB-1052	Improving platelet function following prophylactic platelet transfusion in patients with hematological malignancies	Yi-Feng Wu	Received

PB-1053	Therapeutic Window of a Synthetic Platelet Nanotechnology in New Zealand White Rabbits	Anirban Sen Gupta	Received

PB-1056	Assessment of the haemostatic potential of platelets readied for transfusion	Dermot Cox	Received

PB-1065	Risk factors associated with blood transfusion in liver transplantation	Antoni Sabate	Received

PB-1066	Fibrinogen repletion for perioperative bleeding management: clinical use of cryoprecipitate, fibrinogen concentrate, and target levels used in clinical practice in the United States	Sarah Baker	Received

PB-1068	Management of patients requiring oral anticoagulant reversal for surgical emergencies or major bleeding: clinical practice in the United States	Sarah Baker	Received

PB-1069	Perioperative Management of Major Bleeding: A Survey of Treatment Practices from Members of the American Society of Anesthesiology	Sarah Baker	Received

PB-1076	Reduction of plasma kallikrein by in vivo CRISPR-based gene editing of KLKB1 does not alter coagulation in patients with hereditary angioedema	Stephanie Proulx	Received

PB-1079	Elevated plasma factor XI is associated with postthrombotic syndrome	Anna Hojda	Received

PB-1082	Intratumoral administration of anticoagulant Protein S reduces tumor volume in nude mouse model of pancreatic cancer.	Rinku Majumder	Received

PB-1087	Beyond bleeding: Exploring coagulation factors and cytokines in bone health in vitro	Aline Bernar	Received

PB-1097	Salvianolic Acid B Inhibits Thrombosis and Directly Blocks the Thrombin Catalytic Site	Heyu Ni	Received

PB-1100	Disulfide-bonded Forms of Prothrombin are Differentially Targeted by Anti-Prothrombin Antiphospholipid Antibodies	Mark Schreuder	Received

PB-1104	Understanding distinct conformational states of full-length coagulation Factor VIII and its complex with vWF : A comprehensive AFM analysis	Samhitha Urs Ramaraje Urs	Received

PB-1107	Specific Mutations in Blood Coagulation Factor VIII Have a Cumulative Effect for Increasing its Secretion	Andrey Sarafanov	Received

PB-1112	THE PROCOAGULANT SIGNATURE OF CANCER CELLS DRIVES FIBRIN CLOT SHIELDS FORMATION IN TUMOR MICROENVIRONMENT AND IMPACTS ITS QUALITY. IMPLICATIONS IN CANCER CELL MIGRATION	Patrick Van Dreden	Received

PB-1119	The impact of recombinant factor ? products on inhibitor development in previously untreated and previously treated children with hemophilia A: a systematic review	Jing Sun	Received

PB-1121	Human missense variants in F3 impair the initiation of blood coagulation	Shabbir Ansari	Received

PB-1128	Serial thromboelastography as bleeding and mortality predictors in severe COVID-19 patients	Usi Sukorini	Received

PB-1132	Enhancing adverse drug event surveillance through natural language processing: Focus on hemorragic events identification from clinical narratives	Frédéric Gaspar	Received

PB-1133	Validating the JAKPOT prediction rule for identifying which patients with erythrocytosis are unlikely to have a JAK2 mutation	Barbara Lam	Received

PB-1134	A Swiss National Initiative to develop and validate a multi-modal, multi-source, multi-centric data-driven approach for antithrombotic adverse drug events detection in older inpatients	Claire Coumau	Received

PB-1150	Shear rates in hemorrhagic vascular injury	Gian Rivera Crespo	Received

PB-1159	Tissue-Type Plasminogen Activator-Inhibitor Complex as an Early Predictor of septic liver injury: A Retrospective, SingleCenter Study	Longping He	Received

PB-1161	Investigation of coagulation characteristics in animal blood used for development of cardiovascular devices	Osamu Kumano	Received

PB-1164	A clinical study on establishment and evaluation of autoverification rules for coagulation tests	Lei Zhang	Received

PB-1165	APAC, a heparin proteoglycan mimic, is a potent von Willebrand Factor-mediated antithrombotic over collagen in a microfluidic blood perfusion system under high shear rate	Annukka Jouppila	Received

PB-1169	New 3D-printable, Hemo- and Biocompatible Non-Isocyanate Polyurethane Elastomers for the Manufacturing of Blood-contacting Medical Devices	Sofia Melo	Received

PB-1171	Design, Manufacturing and Testing of a Green Non-Isocyanate Polyurethane Prosthetic Heart Valve	Sofia Melo	Received

PB-1186	Myeloproliferative neoplasms with thrombocytosis and acquired von Willebrand disease: a single centre experience.	Susie Shapiro	Received

PB-1190	Factor VIII inhibitors exhibit either type I or type II kinetics in acquired haemophilia A	Paul Batty	Received

PB-1207	Prevalence of vitamin D deficiency in patients with haemophilia in a Comprehensive Treatment Center in Mexico City.	Maria-Teresa Garcia-Lee	Received

PB-1210	Exploring the Mental Health and Resilience of Youth Diagnosed with Hemophilia: A Scoping Review	Ante Cuvalo	Received

PB-1215	Sequential combined bypassing therapy in congenital haemophilia patients with inhibitors to VIII or IX factors: Surgical experience	Hu Zhou	Received

PB-1220	Cardiovascular Risk Factors in a Large Multi-Institutional Cohort of Persons with Hemophilia	Brandon M Hardesty	Received

PB-1222	Cut-off score for identifying patients at risk of Hemophilia using a Hemophilia self-screening tool in resource-constrained settings	Wulandewi Marhaeni	Received

PB-1223	A study of the mood state for mothers of children with hemophilia	Aya Nakao	Received

PB-1225	Orthopedic assessment in patients with hemophilia and Von Willebrand disease in a mexican population	Yoriko Fabiola Rojas Sato	Received

PB-1227	Using the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) to describe the joint health status in adults with hemophilia	Liz Beatty	Received

PB-1230	APTT sensitivity to mild Haemophilia B, data from 900 participants registered with the UK NEQAS BC programme in 2023.	christopher reilly-stitt	Received

PB-1241	Successfully retinoblastoma surgery in a Severe Hemophilia A with an incomplete impregnation dose of Emicizumab, Instituto Nacional de Pediatria, Mexico city, Mexico	MARA NUNEZ TOSCANO	Received

PB-1260	First report of a Mexican family with F8 c.1443GA mutation causing mild hemophilia	Maria-Teresa Garcia-Lee	Received

PB-1264	The Association between Unemployment and Treatment Among Adults with Hemophilia	Christian Qvigstad	Received

PB-1278	Thrombocytopenia in cardiovascular disease, surgery, and its implicationsInstituto Nacional de Pediatria, Mexico city , Mexico	MARA NUNEZ TOSCANO	Received

PB-1283	Determinants of genotype-phenotype correlations of MYH9 variants: lessons from patients with codon 1424 mutations.	Leah Bhandal	Received

PB-1292	Characterization of three patients with moderate bleeding diathesis and platelet dysfunction associated with novel genetic variants in GP6 and P2RY12	José Rivera Pozo	Received

PB-1293	Genetic Landscape of Inherited Thrombocytopenia: Eight Years of Experiences in a Large Polish Cohort	Bartosz Urbanski	Received

PB-1295	Dose Genotype Correlate with Phenotype Among Glanzmann Thrombasthenia Patients?	Ahmad Tarawah	Received

PB-1298	Heavy menstrual bleeding is a common indication for evaluation for platelet disorders in adolescents.	Michele Lambert	Received

PB-1300	A Rare Familial GP1BA Variant Causing Autosomal Dominant Bernard-Soulier Syndrome	Sonata Saulyte Trakymiene	Received

PB-1303	Identification of a novel mutation in the NBEAL2 gene in a patient with gray platelet syndrome	Tatsuya Konishi	Received

PB-1307	Molecular profiling of a patient with combined thrombocytopenia and connective tissue disorder	Nina Borràs Agustí	Received

PB-1310	May-Hegglin Anomaly: are giant platelets a giant problem?	Markie Zimmer	Received

PB-1327	Searching for a reliably predictive PLASMIC score: Results of a multicenter study	Mouhamed Yazan Abou-Ismail	Received

PB-1328	The therapeutic efficacy of daratumumab in the management of multiply relapsed refractory immune thrombotic thrombocytopenic purpura: an Australian single centre experience.	Pratheepan Puvanakumar	Received

PB-1342	Anti-angiogenic activity of novel plasminogen fragments produced by a bacterial metalloproteinase	ERIKO SUZUKI	Received

PB-1348	Impact of Neutrophil extracellular traps (NETs) on endothelial cell behavior and procoagulant proteins up-regulation	Massoud Mirshahi	Received

PB-1354	Effect of tinzaparin, apixaban, enoxaparin and quercetin and on the expression of procoagulant properties of cancer cells and endothelial cells exposed to cancer cell derived microvesicles	patrick Van Dreden	Received

PB-1355	Aortic endothelial cells response to pulsatile vs continuous flow at high shear stress	Christina Le Tanno	Received

PB-1372	Trajectory of immunothrombosis biomarkers in a fecal-induced peritonitis (FIP) model of murine sepsis	Dhruva Dwivedi	Received

PB-1375	Impact of ticagrelor pretreatment in a cecal slurry mouse model of polymicrobial abdominal sepsis	Alexandre Mansour	Received

PB-1403	Impact of determining clinical risk factors and biomarkers on the risk of cancer-associated thrombosis in newly diagnosed patients with multiple myeloma. The observational Roadmap-CAT-MM	patrick Van Dreden	Received

PB-1404	Management and outcomes in patients with tumor thrombus: A retrospective cohort study	Tzu-Fei Wang	Received

PB-1411	Altered whole blood thrombin generation and hyperresponsive platelets associate with thromboembolic events in patients with pancreatic ductal adenocarcinoma	Ruth Willems	Received

PB-1432	Tissue Factor mRNA (TF mRNA) and Activated FVII-Antithrombin Complex (FVIIa/AT) As Potential Markers of Thrombo-Hemorrhagic Events (THE) in APL Patients	Anna Falanga	Received

PB-1444	Survival effects of intraoperative thromboprophylaxis with low-molecular-weight heparin or heparin in patients undergoing colorectal cancer resection: A post-hoc analysis of PERIOP-01 trial	Tzu-Fei Wang	Received

PB-1446	Direct oral anticoagulants for thromboprophylaxis in multiple myeloma a systematic review and meta-analysis	Catalina Codreanu	Received

PB-1451	Development of Occult Myeloproliferative Neoplasm in Patients with Venous Thromboembolism and JAK2 Positive Mutation: A Systematic Review	Nathalie Loeb	Received

PB-1454	Outpatient antithrombotic prophylaxis during chemotherapy treatment. Experience in clinical practice at Lucus Augusti University Hospital (Lugo, Spain).	Alvaro Lorenzo Vizcaya	Received

PB-1464	Experience with direct oral anticoagulants in hematological malignancies at the Hematology Service of the Clínicas University Hospital. Montevideo-Uruguay	Maria Cecilia Guillermo Esposito	Received

PB-1466	Safety and efficacy of DOACs in cirrhotic and non-cirrhotic splanchnic vein thrombosis: preliminary results from a prospective observational study.	Rosa Talerico	Received

PB-1471	A Multidisciplinary Splanchnic Vein Thrombosis Clinic: Experiences from the First Year	Rushad Patell	Received

ISTH 2024 Congress

June, 22-26 Bangkok

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 22/06/2024 TO 22/06/2024

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access